Table 1.

Epidemiological information and clinical manifestations of patients with peripheral facial paralysis admitted to ENT clinic

Patient no.	PCR	Age	Gender	Side of palsy	Grade at first admission	Treatment type	Treatment duration	Grade after treatment
1	Negative	48	F	Left	3	ITS	2 weeks	1
2	Negative	14	M	Left	5	Systemic	2 weeks	1
3	Negative	74	M	Right	3	ITS	2 weeks	2
4	Negative	47	F	Left	4	ITS	2 weeks	2
5	Negative	73	F	Right	5	ITS	2 weeks	2
6	Negative	24	M	Right	4	Systemic	2 weeks	1
7	Negative	55	F	Right	2	Systemic	2 weeks	1
8	Negative	29	M	Left	3	Combined	4 weeks	2
9	Negative	60	M	Left	2	Systemic	2 weeks	1
10	Negative	35	M	Right	4	Combined	4 weeks	2
11	Negative	19	F	Right	6	Combined	4 weeks	3
12	Negative	71	F	Left	3	Systemic	2 weeks	1
13	Negative	45	M	Right	3	ITS	2 weeks	1
14	Negative	69	F	Left	4	ITS	4 weeks	3
15	Negative	22	F	Left	3	Systemic	2 weeks	1
16	Negative	30	F	Right	3	Combined	4 weeks	2
17	Negative	57	F	Right	4	Systemic	2 weeks	2
18	Negative	59	F	Left	2	Systemic	2 weeks	1
19	Negative	28	M	Left	4	Systemic	2 weeks	1
20	Negative	49	M	Right	4	Systemic	2 weeks	2
21	Negative	59	F	Right	5	ITS	4 weeks	3
22	Negative	42	F	Right	4	ITS	2 weeks	2
23	Negative	34	M	Left	3	Systemic	2 weeks	1
24	Negative	72	M	Right	3	ITS	2 weeks	2
25	Negative	49	F	Left	3	Systemic	2 weeks	1
26	Negative	32	M	Left	4	Systemic	2 weeks	1
27	Positive	90	M	Left	4	ITS	2 weeks	2
28	Positive	4	F	Left	4	Systemic	2 weeks	1
29	Positive	17	F	Right	3	Combined	4 weeks	1
30	Positive	71	F	Right	4	ITS	2 weeks	1
31	Positive	63	F	Left	4	Systemic	4 weeks	2
32	Positive	60	F	Left	4	Systemic	2 weeks	2
33	Positive	65	F	Left	3	ITS	2 weeks	2
34	Positive	30	M	Left	3	Systemic	4 weeks	3

ENT ear-nose-throat; M male; F female; PCR SarS-CoV-2 reverse transcriptase polymerase chain reaction test; ITS intratympanic steroid; Grade House-Brackmann grading scale